Menu
X

Tags Archives: Blood Cancer


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
17 hours ago patient story

**The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma**

**The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma**

patient story

patient story

In the long journey of life, cancer often strikes like a sudden storm, leaving patients and their families devastated. Mrs. Li, a young and resilient mother from China, was no exception. Two years ago, she was diagnosed with relapsed and refractory B-cell non-Hodgkin lymphoma. The shocking news felt like a bolt from the blue, throwing her once-happy family into the depths of despair.

Traditional chemotherapy and radiation therapy once brought a flicker of hope for Mrs. Li, temporarily alleviating her condition. However, fate seemed to play a cruel trick on her again, as the tumor returned with more aggression, no longer responding to conventional treatments. The repeated rounds of therapy took a toll on her body and spirit. Both Mrs. Li and her family were pushed to the brink of collapse, feeling trapped in a deep abyss with no light of hope in sight.

Just when Mrs. Li was about to give up, fate intervened. Thanks to the relentless efforts of the “Advanced Medicine in China” team, they successfully connected Mrs. Li with the country’s top hematology specialists. After a series of communications and coordination, this expert became her last lifeline, taking on the responsibility of devising the best treatment plan during her darkest hours.

After conducting a comprehensive and detailed examination of Mrs. Li, the expert, relying on extensive experience and professional judgment, decisively recommended CAR-T therapy, a cutting-edge treatment. This innovative immunotherapy acts like a magical key, reactivating the patient’s immune system to precisely target and attack cancer cells, offering a new glimmer of life. Faced with this final hope, Mrs. Li carefully considered her options and bravely decided to seize it, determined to fight once more for her life.

The results were truly remarkable. CAR-T therapy produced astonishing effects in Mrs. Li, like a dazzling light in the darkness. After just a few weeks, follow-up tests showed that her tumor had significantly shrunk, and the symptoms that had once plagued her improved dramatically. This was a pivotal moment, allowing Mrs. Li and her family to rediscover hope for the future.

In the months that followed, under close monitoring and consolidation treatment, Mrs. Li’s condition stabilized, as though the ferocious beast of cancer had been tamed. Ultimately, she achieved a miracle—her cancer reached complete remission. For Mrs. Li and her family, this was nothing short of extraordinary, filling their hearts with overwhelming joy and gratitude. They were not only rekindled with the flame of hope for life but also deeply thankful to the “Advanced Medicine in China” team and CAR-T therapy.

As the recommending team, “Advanced Medicine in China” feels honored to have witnessed Mrs. Li’s recovery journey. This is not just a victory for one patient but a successful step forward in the ongoing battle against cancer, inspiring the team to continue seeking rays of hope for more patients. Mrs. Li’s story has become a powerful tale of triumph, spreading rapidly among fellow patients. Her courage and perseverance have set an example for many others bravely fighting blood cancer, encouraging them to press on and never give up.

Through Mrs. Li’s case, CAR-T therapy in China has once again demonstrated its immense potential in the treatment of lymphoma. Like a rising star, it is bringing new hope to blood cancer patients worldwide, illuminating their path toward overcoming the disease. In the future, CAR-T therapy in China will undoubtedly create more miracles, offering patients the dawn of life and a brighter future.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#patientstory #CARTTherapy #CancerSurvivor #Lymphoma #LymphomaTreatment #BloodCancerAwareness#MedicalMiracles #ChinasMedicalAdvances #CancerResearch #PatientStories #HopeAgainstCancer #Immunotherapy #FightCancer #CancerRemission #CourageToFight #BreakthroughInMedicine


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image

Blood Cancer – Diagnosis and Treatment Tips

👍Blood Cancer – Diagnosis and Treatment Tips 👍

Blood Cancer

Blood Cancer

Blood cancer, encompassing types such as leukemia, lymphoma, and multiple myeloma, represents a significant health challenge in regions like Southeast Asia and India. These hematologic malignancies arise from blood-forming cells and can impact the bone marrow, blood, and various organs. The increasing prevalence of these diseases is concerning, yet advancements in diagnosis and treatment provide hope for patients.

## Understanding Hematologic Malignancies

💥Hematologic malignancies include a variety of cancers such as:

– **Leukemia**: Cancer of the bone marrow that leads to the overproduction of abnormal white blood cells.

– **Lymphoma**: Affects the lymphatic system and includes #Hodgkin and #nonHodgkinlymphoma.

– **Multiple Myeloma**: Cancer that forms in plasma cells, affecting the production of antibodies.

🌟The causes of these conditions are multifactorial, involving genetic factors, immune dysfunction, exposure to environmental toxins, and lifestyle choices. For instance, a diet high in processed foods, sedentary behavior, and high stress levels can contribute to an increased risk of developing these cancers.

## The Rising Incidence of Blood Cancer

The incidence of blood cancers is on the rise globally, particularly in countries with aging populations. In Southeast Asia and India, there has been a noticeable increase in cases of leukemia and lymphoma, necessitating better awareness and improved healthcare infrastructure.

## Diagnosis: Early Detection is Key

Early diagnosis is crucial for successful treatment outcomes. Patients experiencing symptoms such as unexplained fatigue, frequent infections, easy bruising, or swollen lymph nodes should seek medical advice promptly. Healthcare providers may utilize blood tests, bone marrow biopsies, and imaging studies to diagnose these conditions accurately.

## Treatment Advances: A Diverse Approach

Recent years have seen significant advancements in the treatment of hematologic malignancies, offering patients more options than ever before:

1. **Combination Chemotherapy**: Despite potential side effects, combination chemotherapy remains a cornerstone treatment. New regimens are being developed that combine traditional cytotoxic drugs with targeted therapies and immunotherapies to enhance efficacy and reduce toxicity.

2. **Targeted Therapies**: Drugs that specifically target cancer cell mutations or characteristics are revolutionizing treatment. For example, *Gleevec*, the first targeted therapy, has dramatically improved survival rates for chronic myeloid leukemia (#CML).

3. **Monoclonal Antibodies**: Often dubbed “biological missiles,” these treatments target specific proteins on cancer cells, allowing for more precise treatment with fewer side effects.

4. **Hematopoietic Stem Cell Transplantation**: This procedure remains one of the most effective treatments for certain types of blood cancer, especially when other treatments fail.

5. **Immunotherapy**: This approach harnesses the body’s immune system to fight cancer. Techniques like CAR-T cell therapy, which modifies a patient’s T cells to attack cancer cells, have shown promising results in treating various hematologic malignancies. China is at the forefront of CAR-T cell therapy research and application, particularly in treating hematologic malignancies. CAR-T therapy involves extracting a patient’s T cells, modifying them to specifically recognize and attack cancer cells. Clinical research and applications in China have shown remarkable effectiveness in treating leukemia, lymphomas, and multiple myeloma. Some studies indicate that patients receiving CAR-T treatment experience significantly higher long-term survival rates and lower recurrence rates. Furthermore, China has made significant progress in the standardization of CAR-T therapy, personalized treatment plans, and the development of technological platforms, enabling more patients to benefit from this innovative treatment.

## Hope for the Future

Countries like India and those in Southeast Asia are rapidly advancing in the field of blood cancer treatment. Collaborative efforts among healthcare professionals, research institutions, and patient advocacy groups are crucial for improving access to cutting-edge therapies. The development of treatment guidelines tailored to the regional context can ensure that patients receive the best possible care.

### Conclusion

Hematologic malignancies are challenging but treatable diseases. Through early diagnosis and the application of innovative therapies, patients can achieve significant improvements in their health and quality of life. As research continues to evolve, the prospect of long-term survival and even cures for blood cancers is becoming increasingly attainable. Empowering patients with knowledge and access to modern treatments is essential to fighting blood cancer effectively in #SoutheastAsia and #India.

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
2 weeks ago Myeloma

**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient**

**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient**

Multiple Myeloma

Multiple Myeloma

#MultipleMyeloma #CARTtherapy #BloodCancer #CompleteRemission #CART

 

    Multiple Myeloma (MM) is a malignant blood disorder characterized by abnormal proliferation of plasma cells, which causes damage to vital organs. Patients with high-risk cytogenetic abnormalities like 17p deletion, t(4;14) translocation, and t(14;16) translocation face an even worse prognosis. While new drugs like proteasome inhibitors and autologous stem cell transplantation have improved MM treatment outcomes, relapsed/refractory multiple myeloma (RRMM) continues to be a challenge due to its aggressive nature and tendency to relapse. Despite the use of traditional therapies, many patients either fail to respond or cannot tolerate further treatment due to underlying health issues.

    CAR-T cell therapy, a novel immunotherapy that re-engineers the patient’s own T cells to attack cancer cells, has shown remarkable results in RRMM patients. It offers an alternative for patients who have poor tolerance to conventional treatments, presenting a safer and more effective option. In particular, Equecabtagene Autoleucel, a CAR-T therapy targeting the BCMA antigen on myeloma cells, has demonstrated success in treating patients unresponsive to frontline therapies.

### Case Study: High-Risk MM Patient Achieves Complete Remission

A 45-year-old male patient diagnosed with high-risk multiple myeloma in June 2023 sought further treatment at our hospital after failing to respond to chemotherapy. He had a history of coronary artery disease, diabetes, hypertension, and kidney artery stenosis, making traditional therapies less effective and risky.

    Upon evaluation, the patient’s tests indicated κ-type M protein and abnormal free light chains (FLC-κ of 2410.5mg/L). Imaging scans revealed extensive bone damage caused by multiple myeloma. Genetic testing showed high-risk markers including 17p deletion and 1q21 amplification, further complicating his prognosis.

    Given his high-risk status and poor response to standard treatments, the medical team decided to proceed with CAR-T cell therapy using Equecabtagene Autoleucel. After a smooth cell collection and lymphodepletion process, the patient received CAR-T infusion on November 15, 2023.

### Treatment Outcome and Safety

Eight days after infusion, the patient developed a mild fever, indicating cytokine release syndrome (CRS), which was effectively managed with symptomatic treatment. Despite mild kidney dysfunction and temporary blood cell reductions, no severe side effects or neurotoxicities occurred. By day 42, the patient developed a lung infection, which was treated with antibiotics, leading to a full recovery.

    At the one-month follow-up, flow cytometry showed no minimal residual disease (MRD), confirming the patient had achieved complete remission (CR) with MRD negativity. This outcome was particularly significant considering the patient’s failure to respond to previous treatments.

### A Promising Future for High-Risk MM Patients

This case highlights the potential of CAR-T cell therapy, particularly Equecabtagene Autoleucel, in achieving deep remission for high-risk multiple myeloma patients who fail to respond to conventional therapies. With ongoing advancements in biomedical technology and immunotherapy, CAR-T treatments offer hope for RRMM patients, providing longer disease-free survival and improved quality of life.

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#ChinaMedicalAdvances #InnovativeTreatments #Immunotherapy #EquecabtageneAutoleucel #CancerResearch


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
2 weeks ago CAR-T

The significance of the 11 CD19 and BCMA CAR-T therapies currently approvedin China and the U.S. forpatients with hematologic malignancies.

The significance of the 11 CD19 and BCMA CAR-T therapies currently approvedin China and the U.S. forpatients with hematologic malignancies.

目前中美上市的11款CD19和BCMA CAR-T对血液瘤患者的意义

Expert:

**Jing Pan**

**Associate Chief Physician**

**Department of Pediatric Hematology, Beijing Gaobo Hospital**

**Professional Memberships:**

– Member, Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association

– Youth Committee Member, Hematologic Oncology Professional Committee of the Chinese Anti-Cancer Association

– Youth Committee Member, Clinical Application Professional Committee of the Chinese Medical Biotechnology Association

**Expertise:**

Dr. Pan currently manages an 80-bed pediatric hematology unit and has extensive experience in pediatric hematology, particularly in CAR-T cell immunotherapy, with nearly 10 years of experience in the field. She is dedicated to stratified CAR-T treatment, optimizing the management of complications during CAR-T therapy, and establishing an efficacy monitoring system post-treatment. Dr. Pan and her team have accumulated one of the largest single-center case collections globally, particularly in the areas of sequential CAR-T therapy for improving long-term outcomes in B-ALL and in exploring autologous and allogeneic CD5, CD7 CAR-T therapy for T-ALL/LBL.

Her related clinical research on CD7 CAR-T, CD19 CAR-T, CD22 CAR-T, and CD19-22 sequential CAR-T has been published in leading international journals such as *Lancet Oncology*, *JCO*, *Blood*, *JHO*, and *Leukemia*. Additionally, she has frequently presented the latest advancements in her team’s immunotherapy research at both domestic and international conferences, including ASCO, ASH, EHA, and JSH.

潘 静
副主任医师
北京高博医院 小儿血液科
中国抗癌协会小儿肿瘤专业委员会专业委员
中国抗癌协会血液肿瘤专业委员会青年委员
中国医药生物技术协会医药生物技术临床应用专业委员会青年委员
擅长:
目前独立管理床位数80张的儿童血液病区。从事儿童血液科临床工作多年,特别是在儿童CAR-T细胞免疫治疗方面积累了近10年的经验。致力于CAR-T的分层治疗,优化CAR-T治疗过程中的并发症处理,建立CAR-T治疗后的疗效监控体系。尤其是其带领团队在序贯CAR-T提高B-ALL远期预后,T-ALL/LBL的自体、异体CD5、CD7CAR-T治疗探索方面目前积累了全球较大的单中心病例数。相关的CD7CAR-T临床研究、CD19CAR-T临床研究、CD22CAR-T临床研究、CD19-22序贯CAR-T研究等,发表在国际血液病权威杂志期刊Lancet on-cology、JC0、Blood、JHO和Leukemia。并多次在国内外学术会议(美国临床肿瘤大会ASCO、美国血液年会ASH、欧洲血液年会EHA、日本血液年会JSH)汇报团队免疫治疗的最新进展。

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#cart #carttherapy #CAR_T #leukemia #lymphoma #cancer #tumor #bloodcancer


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
3 weeks ago CAR-T

Can the Million-dollar Anti-cancer Injection “Cure” Tumors?

Can the Million-dollar Anti-cancer Injection “Cure” Tumors?

Is CAR-T therapy really a “one-shot cure”?

And how can we ensure that this CAR “drives well and drives long”?

百万抗癌针能“治愈”肿瘤吗?

如何让CAR“开得好,开得久?”

Expert:

**Jing Pan**

**Associate Chief Physician**

**Department of Pediatric Hematology, Beijing Gaobo Hospital**

**Professional Memberships:**

– Member, Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association

– Youth Committee Member, Hematologic Oncology Professional Committee of the Chinese Anti-Cancer Association

– Youth Committee Member, Clinical Application Professional Committee of the Chinese Medical Biotechnology Association

**Expertise:**

Dr. Pan currently manages an 80-bed pediatric hematology unit and has extensive experience in pediatric hematology, particularly in CAR-T cell immunotherapy, with nearly 10 years of experience in the field. She is dedicated to stratified CAR-T treatment, optimizing the management of complications during CAR-T therapy, and establishing an efficacy monitoring system post-treatment. Dr. Pan and her team have accumulated one of the largest single-center case collections globally, particularly in the areas of sequential CAR-T therapy for improving long-term outcomes in B-ALL and in exploring autologous and allogeneic CD5, CD7 CAR-T therapy for T-ALL/LBL.

Her related clinical research on CD7 CAR-T, CD19 CAR-T, CD22 CAR-T, and CD19-22 sequential CAR-T has been published in leading international journals such as *Lancet Oncology*, *JCO*, *Blood*, *JHO*, and *Leukemia*. Additionally, she has frequently presented the latest advancements in her team’s immunotherapy research at both domestic and international conferences, including ASCO, ASH, EHA, and JSH.

潘 静

副主任医师

北京高博医院 小儿血液科

中国抗癌协会小儿肿瘤专业委员会专业委员

中国抗癌协会血液肿瘤专业委员会青年委员

中国医药生物技术协会医药生物技术临床应用专业委员会青年委员

擅长:

目前独立管理床位数80张的儿童血液病区。从事儿童血液科临床工作多年,特别是在儿童CAR-T细胞免疫治疗方面积累了近10年的经验。致力于CAR-T的分层治疗,优化CAR-T治疗过程中的并发症处理,建立CAR-T治疗后的疗效监控体系。尤其是其带领团队在序贯CAR-T提高B-ALL远期预后,T-ALL/LBL的自体、异体CD5、CD7CAR-T治疗探索方面目前积累了全球较大的单中心病例数。相关的CD7CAR-T临床研究、CD19CAR-T临床研究、CD22CAR-T临床研究、CD19-22序贯CAR-T研究等,发表在国际血液病权威杂志期刊Lancet on-cology、JC0、Blood、JHO和Leukemia。并多次在国内外学术会议(美国临床肿瘤大会ASCO、美国血液年会ASH、欧洲血液年会EHA、日本血液年会JSH)汇报团队免疫治疗的最新进展。

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
3 weeks ago Myeloma

Uncovering the Hidden Threat: How Serum Protein Electrophoresis Helps Diagnose Multiple Myeloma

**Uncovering the Hidden Threat: How Serum Protein Electrophoresis Helps Diagnose Multiple Myeloma**

Serum Protein Electrophoresis

Serum Protein Electrophoresis

As we age, it’s common to experience certain health issues—unexplained anemia, bone pain, fractures, nausea, or abnormal urine changes. Many may dismiss these symptoms as a result of aging, poor diet, or even mild illness. However, such seemingly unrelated signs could indicate a more serious condition: **Multiple Myeloma (MM)**.

**What is Multiple Myeloma (MM)?**

Multiple Myeloma is a type of blood cancer that originates in the bone marrow, where abnormal plasma cells multiply uncontrollably. These malignant cells produce large amounts of a protein called **M-protein** (monoclonal protein), leading to damage in various organs such as the kidneys and bones. The condition is complex, with different patients exhibiting diverse symptoms, often making it challenging to diagnose early. Key factors contributing to MM include genetic mutations and chromosomal changes, alongside abnormalities in the bone marrow microenvironment.

**Why is Early Detection Crucial?**

Over the past few decades, MM cases have steadily increased, particularly among older adults. Delayed diagnosis can result in severe complications, impacting the patient’s quality of life. Due to its subtle onset and wide range of symptoms, many MM patients may see multiple specialists without receiving the correct diagnosis. This makes raising awareness of MM screening critical—early detection can significantly improve survival and quality of life.

One of the most effective tools for early diagnosis is **Serum Protein Electrophoresis (SPE)**—a simple yet powerful lab test that can detect the presence of abnormal proteins, such as M-protein, in the blood.

**How Serum Protein Electrophoresis (SPE) Works**

SPE works by separating the proteins in your blood serum based on their size and electrical charge. Imagine it like children sliding down a playground slide, each going at different speeds depending on their size and shape. Similarly, proteins in the blood move at varying speeds in an electric field. This separation allows us to visualize distinct “protein bands” that represent different proteins like albumin and globulins. For MM patients, the presence of a sharp spike (M-protein) in the **gamma globulin region** serves as a telltale sign of the disease.

This method not only helps in identifying MM but also plays a key role in monitoring disease progression and assessing the effectiveness of treatment. By measuring the quantity of M-protein, doctors can gauge the severity of the disease and tailor therapies accordingly.

**Beyond Multiple Myeloma: Other Uses of SPE**

While SPE is essential for diagnosing MM, it is also a useful tool for identifying other conditions, including **liver diseases**, **kidney disorders**, and **chronic infections**. For example, in patients with liver cirrhosis, SPE often shows an increase in **beta and gamma globulin**, creating a distinctive pattern called a **beta-gamma bridge**. Similarly, kidney disease patients typically exhibit reduced albumin levels. By analyzing these patterns, doctors gain deeper insights into the underlying health issues.

**Other Diagnostic Tools for MM**

In addition to SPE, there are several other lab tests and imaging techniques that can help detect MM. These include **complete blood counts (CBC)**, **kidney function tests**, **calcium levels**, and imaging such as **X-rays** or **MRIs**. Research has shown that combining various tests, such as hemoglobin, globulin, HDL cholesterol, and uric acid, enhances the early detection of MM.

**A Complex Disease with Varied Outcomes**

Though multiple myeloma remains incurable, treatments can significantly extend survival, especially when caught early. If you or someone you know is experiencing unexplained symptoms like persistent anemia, unusual bone pain, or kidney issues, it’s essential to seek evaluation by a hematologist. Timely diagnosis and treatment are critical to improving both prognosis and quality of life.

**Stay informed, stay vigilant, and prioritize early screening** to protect yourself from the silent threat of multiple myeloma.

To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070 (Https://wa.me/+8613717959070)

Email: doctor.huang@globecancer.com

#MultipleMyeloma #BloodCancer #CancerAwareness #EarlyDiagnosis #SerumProteinElectrophoresis #HealthTips #MMResearch #CancerScreening #BloodTests #HealthyAging #MedicalBreakthrough


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image

Hematologic Tumors – Detection: Unveiling the Mysteries of the Disease

**🩸Hematologic Tumors🩸** – 🩺Detection🩺:

Unveiling the Mysteries of the Disease

可能是包含下列内容的图片:医院和文字

Hematologic tumors are a group of malignant diseases caused by the abnormal proliferation of blood-forming cells, affecting the bone marrow, blood, and various organs and tissues throughout the body. Common types of hematologic tumors include leukemia, myelodysplastic syndromes, lymphoma, multiple myeloma, and myeloproliferative neoplasms.

### Causes of Hematologic Tumors

The development of hematologic tumors is highly complex. Key factors include genetic mutations, immune system abnormalities, radiation exposure, contact with harmful chemicals, viral infections, and hereditary factors. Additionally, unhealthy lifestyle habits, prolonged psychological stress, and poor environmental conditions can increase the risk of these diseases.

In recent years, due to global population aging and modern lifestyle changes, the incidence of hematologic tumors has been on the rise. In China, leukemia and lymphoma rank among the top malignant tumors in terms of incidence and mortality. Therefore, early detection and accurate diagnosis of hematologic tumors are crucial for improving patient outcomes.

### Detection Methods for Hematologic Tumors

Since early symptoms of hematologic tumors are often subtle, many patients are diagnosed in the late stages of the disease. Thus, early detection is essential. The medical field has developed a variety of advanced and precise diagnostic methods to detect and confirm hematologic tumors.

#### 1. **Blood Tests**

A complete blood count (CBC) is a fundamental tool for detecting hematologic tumors. By analyzing the quantity and morphology of red blood cells, white blood cells, and platelets, physicians can preliminarily identify abnormalities. For example, leukemia patients often exhibit abnormal increases or decreases in white blood cells, along with immature cells in the bloodstream.

#### 2. **Bone Marrow Biopsy**

Bone marrow biopsy is a key diagnostic method for hematologic tumors. By analyzing the hematopoietic cells from a bone marrow sample, physicians can determine the presence of abnormal or malignant cell proliferation. This procedure not only confirms the type of hematologic tumor but also helps assess disease progression and treatment efficacy.

#### 3. **Flow Cytometry**

Flow cytometry is an efficient method for detecting hematologic tumors. It rapidly analyzes characteristic markers on the surface of cells, helping doctors identify and quantify abnormal cells. It plays an essential role in diagnosing diseases such as leukemia and lymphoma.

#### 4. **Genetic Testing**

Genetic mutations are a critical factor in many hematologic tumors. Genetic testing can reveal the mutation profile within a patient’s cells, enabling doctors to better understand the underlying cause of the disease and formulate personalized treatment plans. With advancements in molecular biology, genetic testing has become a cornerstone of precision medicine.

#### 5. **Imaging Tests**

For certain aggressive hematologic tumors, imaging tests like CT, PET-CT, and MRI help doctors assess the extent and spread of the disease. These techniques are particularly valuable in staging and evaluating the treatment response of lymphomas.

### Conclusion

The detection of hematologic tumors has become increasingly accurate, greatly improving early diagnosis rates and treatment outcomes. By effectively utilizing blood tests, bone marrow biopsies, flow cytometry, genetic testing, and imaging, patients can receive earlier diagnoses and more tailored treatment plans. With continuous advances in medical technology, the cure rates for hematologic tumors are expected to rise, bringing hope for better health to more patients.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp:+8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#HematologicCancer #BloodCancer #CancerDetection #LeukemiaAwareness #LymphomaAwareness #MultipleMyeloma #CancerDiagnosis #GeneticTesting #EarlyDetection #FlowCytometry #BoneMarrowBiopsy #CancerResearch #PrecisionMedicine #CancerTreatment #Immunotherapy #Oncology #CancerAwareness #HealthInnovation #MedicalAdvancements #CancerCare


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
2 months ago Myeloma

Multiple Myeloma Solution ** Breakthroughs and Hope in Blood Cancer Treatment**

Multiple Myeloma Solution

** Breakthroughs and Hope in Blood Cancer Treatment**

Mutiple Myeloma

Mutiple Myeloma

Multiple myeloma is a malignant blood cancer caused by the abnormal proliferation of plasma cells in the bone marrow, often affecting the bones, kidneys, and various organs and systems. With the advancement of modern medical technology, the understanding and treatment of multiple myeloma have greatly improved, bringing unprecedented hope to patients.

### Causes and Risk Factors of Multiple Myeloma

The causes of multiple myeloma are complex, typically involving multiple factors such as genetic mutations, immune system abnormalities, exposure to harmful chemicals, viral infections, and genetic predisposition. Additionally, lifestyle and environmental factors like smoking, obesity, and certain occupational exposures are also believed to increase the risk of developing the disease. With an aging population, the incidence of multiple myeloma is on the rise.

### Evolution of Treatment: Traditional and Innovative Approaches

Although multiple myeloma was once considered a difficult-to-treat disease, recent advancements in treatment methods have made significant progress. Traditional treatments include chemotherapy, radiation therapy, and bone marrow transplantation, which have extended patients’ survival to some extent but come with limited efficacy and significant side effects.

However, with advances in medical technology, new treatment options have emerged. Monoclonal antibodies have played a key role in treating multiple myeloma, targeting cancer cells precisely while reducing harm to healthy cells. Antibody-drug conjugates take this a step further by delivering chemotherapy drugs directly to cancer cells, enhancing efficacy while minimizing side effects.

Small molecule targeted drugs represent another breakthrough. These drugs inhibit specific genes or proteins in cancer cells, preventing their growth and spread. For example, BCL-2 inhibitors and protein kinase inhibitors have shown promising results in clinical trials, offering more treatment options.

### Immunotherapy: Leading the Future of Hope

Immunotherapy is becoming increasingly important in the treatment of blood cancers, especially in the field of multiple myeloma. By activating the patient’s own immune system to attack cancer cells, immunotherapy holds great promise. Among the most forward-looking therapies is CAR-T cell therapy. This treatment involves genetically modifying a patient’s T cells to recognize and kill cancer cells, and it has achieved remarkable results in multiple myeloma patients.

In recent years, China has made significant progress in the research and application of immunotherapy. Particularly in the field of blood cancers, China has developed a comprehensive treatment system with established protocols and consensus. The BCMA-targeted CAR-T cell therapy has shown deep and lasting efficacy in treating multiple myeloma, greatly improving patients’ disease-free survival rates. For instance, China’s fully human BCMA-targeted CAR-T product, Equecabtagene Autoleucel, has demonstrated the best data among CAR-T products for multiple myeloma, with a complete remission rate of 82.4%.

### Looking Ahead

With the continuous emergence of new drugs and therapies, the treatment of multiple myeloma is moving towards individualized and precision medicine. Patients not only experience extended lifespans but also regain their quality of life, returning to normalcy in their everyday lives and work. As medical advancements continue, there is reason to believe that multiple myeloma will no longer be an incurable disease, and every patient will be able to embrace a brighter future.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070  (Http://wa.me/+8613717959070)

Email: doctor.huang@globecancer.com


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image

Blood Cancer Solution Including leukemia, lymphoma, multiple myeloma, and others.

👍Blood Cancer Solution👍

💪Including leukemia, lymphoma, multiple myeloma, and others.

Blood Cancer

Blood Cancer

#leukemia #lymphoma #multiplemyeloma

#Hematologic malignancies are a group of malignant diseases originating from hematopoietic cells, often affecting the bone marrow, blood, and various organs and tissues throughout the body. Common types of hematologic malignancies include leukemia, myelodysplastic syndromes, lymphomas, multiple myeloma, and myeloproliferative neoplasms.

The causes of these diseases are complex, involving genetic mutations, immune abnormalities, radiation exposure, contact with harmful chemicals, infections, and hereditary factors. Additionally, poor lifestyle habits, high levels of stress, and environmental factors can also increase the risk of developing these conditions.

With an aging population and advancements in medical technology, the incidence of hematologic malignancies has been rising globally. In China, the incidence and mortality rates of leukemia and lymphoma are now among the top ranks of all malignancies.

However, hematologic malignancies are not incurable. In recent years, the treatment methods for these diseases have seen significant progress. From traditional combination chemotherapy and radiotherapy to hematopoietic stem cell transplantation, monoclonal antibody therapy, antibody-drug conjugates, small molecule targeted therapies, and the latest immunotherapies, treatment options have become increasingly diverse and precise.

Combination chemotherapy remains a primary treatment for many hematologic malignancies, despite its significant side effects. The efficacy of these treatments cannot be ignored. Modern chemotherapy regimens are continually being refined, including the incorporation of new cytotoxic drugs and targeted therapies, as well as the use of monoclonal antibodies. Additionally, the appropriate use of antiemetics, hematopoietic growth factors, and anti-infective agents helps to mitigate adverse effects.

Hematopoietic stem cell transplantation continues to be one of the most effective treatments for certain hematologic malignancies. The development of this treatment in China has been rapid, with 170 registered transplant centers by 2020.

Monoclonal antibodies, often referred to as “biological missiles,” have a high degree of specificity and single biological activity. They have revolutionized the treatment of hematologic malignancies. Antibody-drug conjugates (ADCs) utilize monoclonal antibodies to accurately identify tumor cell markers, guiding the delivery of chemotherapy drugs for targeted treatment.

Small molecule targeted therapies work by interfering with specific genes or proteins to inhibit tumor cell growth and proliferation. Gleevec, the first small molecule targeted therapy, increased the five-year survival rate for chronic myeloid leukemia (CML) patients from 30% to 89%, marking a breakthrough in cancer treatment. Today, there are numerous small molecule targeted drugs available for the treatment of hematologic malignancies, including BCR-ABL inhibitors, BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, and XPO1 inhibitors, with many more drugs currently in clinical trials expected to become available soon.

Immunotherapy includes immune checkpoint inhibitors (such as PD-1/L1), cancer vaccines, cellular immunotherapies (such as #CART), and nonspecific immunomodulatory treatments. #CARTtherapy, in particular, has gained widespread attention as an emerging curative treatment. This approach involves extracting a patient’s T cells, modifying them outside the body to specifically recognize and attack tumor cells, and then reinfusing the modified T cells into the patient. This therapy has been successfully applied to various hematologic malignancies, including acute lymphoblastic leukemia, lymphomas, and multiple myeloma. The first patient treated with CAR-T therapy has been disease-free for 11 years.

In recent years, China has made significant advances in the treatment of hematologic malignancies. The establishment of the “Chinese Expert Consensus on the Diagnosis and Treatment of High-Risk Multiple Myeloma” and the presentation by Professor Huang He at the 2024 #EHA conference on targeting CD7 universal CAR-T therapy for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) have shown remarkable efficacy and safety. Additionally, exciting new data from the 2024 American Society of Clinical Oncology (#ASCO) annual meeting highlighted the efficacy of Relma-cel in treating relapsed/refractory large B-cell lymphoma (R/R LBCL), with a four-year overall survival rate (#OS) of 66.7%. Particularly noteworthy is the research on multiple myeloma, where the BCMA-targeted CAR-T therapy has demonstrated deep and lasting responses, with a complete response (#CR) rate of 82.4% and a 12-month progression-free survival (#PFS) rate of 85.5%.

With the continuous development of new treatments and the emergence of new drugs, hematologic malignancies in China are no longer considered incurable diseases. Through standardized, individualized, and precise treatments, many patients with hematologic malignancies can achieve long-term disease-free survival, and even a cure, returning to normal work and life. As medicine continues to advance, every life will continue to shine brightly!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com👍


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
3 months ago Myeloma

**2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients**

**2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients**

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma (MM) is a malignant plasma cell disorder and one of the most common hematologic malignancies. In China, approximately 20,000 new cases of newly diagnosed multiple myeloma (NDMM) are reported annually, with a median age at diagnosis over 60 years. It is reported that Chinese MM patients generally exhibit higher rates of cytogenetic abnormalities, with an incidence rate exceeding 40%, which is significantly higher than in Western countries.

High-risk MM patients often respond poorly to existing treatment regimens and face limited treatment options. Many elderly patients are frail and have multiple comorbidities, making them less tolerant of the adverse reactions associated with current therapies, particularly autologous stem cell transplantation (ASCT). Once the disease progresses to a refractory/relapsed state, the combination of advanced age, frailty, and high-risk cytogenetic abnormalities leads to limited salvage treatment options, worsening efficacy, and poor prognosis. Thus, selecting effective frontline therapy for NDMM patients, especially high-risk elderly patients unsuitable for transplantation, is a pressing clinical need, requiring innovative therapies to supplement existing treatments. The new generation of cell immunotherapies, exemplified by Equecabtagene Autoleucel, holds promise to fill this gap and potentially become a breakthrough for high-risk NDMM.

In the FUMANBA-1 study, which included 69.5% high-risk patients, Equecabtagene Autoleucel achieved an ORR of 96.1% and has been approved in China for treating third-line or later relapsed/refractory multiple myeloma (R/R MM) patients. This EHA meeting is the first to present oral data on the efficacy and safety of Equecabtagene Autoleucel in the FUMANBA-2 study for high-risk, newly diagnosed, transplant-ineligible MM patients.

### Study Introduction

FUMANBA-2 is a multicenter, open-label, single-arm Phase I study designed to evaluate the efficacy and safety of Equecabtagene Autoleucel in transplant-ineligible NDMM patients with 100% high-risk features (defined by mSMART 3.0: RISS Stage III, double-hit, or triple-hit). Patients received four cycles of induction therapy, including the VRd regimen (Bortezomib, Lenalidomide, Dexamethasone), the VCD regimen (Bortezomib, Cyclophosphamide, Dexamethasone), or the PAD regimen (Bortezomib, Doxorubicin, Dexamethasone). After the third cycle of induction therapy, T cells were collected from patients unsuitable for ASCT and Equecabtagene Autoleucel was prepared. After lymphodepletion, patients received a single infusion of Equecabtagene Autoleucel at a dose of 1.0 x 10^6 CAR-T cells/kg. The primary efficacy endpoints were the proportion of MRD-negative patients and progression-free survival (PFS). Secondary endpoints included objective response rate, duration of response, safety, pharmacokinetics, and pharmacodynamics.

### Study Results

As of January 25, 2024, 16 patients received Equecabtagene Autoleucel, with a median age of 58.5 years (51-69) and a median follow-up time of 13.1 months (7.9-24.3). All patients had high-risk cytogenetics, with 62.5% (10/16) being double-hit, 12.5% (2/16) being triple-hit, and 25% (4/16) having extramedullary disease. 37.5% (6/16) were R-ISS Stage III, with one patient each combining R-ISS Stage III with double-hit and triple-hit characteristics.

The median follow-up time after Equecabtagene Autoleucel infusion was 7.46 months (2.8-18.1). The median PFS was not reached, with a 12-month PFS rate of 84.4% (95% CI: 49.31-96.00). All subjects achieved MRD negativity, with 71.4% (95% CI: 25.8-92.0) maintaining MRD negativity for over 12 months. The objective response rate (ORR) was 100%, with 93.8% (15/16) achieving stringent complete response (sCR).

Grade 1-2 cytokine release syndrome (CRS) occurred in 68.8% (11/16) of patients, with no grade 3 or higher CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), or neurotoxicity. The most common grade 3 or higher drug-related adverse events were hematologic, with a 25.0% (4/16) incidence of grade 3 or higher infectious disease adverse events.

The median peak CAR copy number in peripheral blood was reached on day 10 (7-21) post-infusion, with a median peak level of 79,681.299 copies/μg gDNA. 81.25% (13/16) of patients achieved free B cell maturation antigen (sBCMA) clearance within one month post-infusion. Median peak levels of inflammatory cytokines IL-6, CRP, and ferritin were 64.28 pg/mL (9.12-3017.83), 49.30 mg/L (3.66-117.30), and 553.35 ng/mL (68.10-2349.00), respectively. The median peak times for IL-6 and CRP were day 7 and day 10, respectively, with no significant change in serum ferritin levels compared to pre-infusion.

### Study Outlook

The FUMANBA-2 study of Equecabtagene Autoleucel demonstrates the efficacy and safety of a novel fully human BCMA CAR-T therapy in high-risk, transplant-ineligible, newly diagnosed multiple myeloma patients. This is the first international report of CAR-T therapy as frontline treatment in this specific population. The study highlights the potential application of cell immunotherapy in the MM field. Compared to traditional chemotherapy and new drug treatments, frontline CAR-T therapy for NDMM has the potential to further improve response rates, extend survival, and improve prognosis, particularly for high-risk cytogenetic abnormalities and high tumor burden. For elderly and frail patients who are unsuitable for hematopoietic stem cell transplantation, CAR-T therapy may fill the treatment gap to some extent. The one-time treatment approach, as opposed to continuous chemotherapy or multiple transplants, offers patients better quality of life and treatment convenience. Although CAR-T therapy carries risks such as CRS and neurotoxicity, these side effects are manageable in many studies, and safety improves with treatment experience and management strategies. Bringing CAR-T therapy to the frontline provides patients with more diverse and promising treatment options. However, large-scale, long-term follow-up studies are needed to validate its long-term efficacy and survival benefits, and further exploration and optimization are required for the best administration timing, regimen, and duration.

In summary, the FUMANBA-2 study of Equecabtagene Autoleucel shows significant treatment potential in newly diagnosed, transplant-ineligible multiple myeloma patients. With accumulating research evidence and advances in CAR-T technology, we anticipate CAR-T therapy will benefit more patients in the future.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#EquecabtageneAutoleucel #MultipleMyeloma #MMTreatment #HighRiskMM #NDMM #CAR_Therapy #Immunotherapy #BloodCancer #OncologyResearch #EHA2024 #CancerBreakthrough #CellTherapy #MyelomaTreatment #ClinicalTrials #InnovativeMedicine #HealthcareAdvancements


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
4 months ago CAR-T

**2024 ASCO: National Institute’s New CAR-T Therapy CD7 CAR-T Cells, Multiple Blood Cancer Destroyers**

**2024 ASCO: National Institute’s New CAR-T Therapy CD7 CAR-T Cells, Multiple Blood Cancer Destroyers**

CAR-T Therapy

CAR-T Therapy

**2024 ASCO: Four Chinese-developed CAR-T therapies make a significant impact, targeting colorectal cancer, pancreatic cancer, and hematological tumors, with an overall response rate nearing 100.0%**

 

**CD7 CAR-T Cells: A Powerful Strike Against Hematological Tumors, Patients Achieve Complete Remission**

 

Patients with relapsed or refractory hematologic malignancies have limited treatment options and poor prognosis, with a 5-year overall survival rate of less than 20%. While allogeneic hematopoietic stem cell transplantation (HSCT) provides a critical strategy for treating aggressive hematologic cancers, HSCT treatment can also result in adverse reactions such as graft-versus-host disease (GVHD) and conditioning-related toxicities. Additionally, some patients with poor health cannot undergo this treatment. Therefore, new treatment methods are urgently needed, and the emergence of CAR-T therapy has brought new hope to patients with hematologic tumors.

 

The world-renowned journal, *The New England Journal of Medicine*, reported on a clinical study of “CD7 CAR-T cells for the treatment of relapsed or refractory CD7-positive hematologic tumors” (NCT04599556).

 

From November 2021 to September 2023, 10 patients with relapsed or refractory CD7-positive cancers were enrolled in the study, including 7 cases of acute myeloid leukemia (AML), 2 cases of T-cell acute lymphoblastic leukemia (ALL), and 1 case of T-cell lymphoblastic lymphoma (IVA stage). The median age was 56.5 years (range, 13.7–72.5 years). All patients had bone marrow involvement, with a median blast cell percentage of 36.0% (range, 2–87), and a median CD7 expression on blast cells of 93.0% (range, 80.7–97.7). All patients had received extensive prior treatments, with a median of 9.5 courses (range, 4–15 courses). After enrollment, patients first received an intensive lymphocyte-depleting regimen (cyclophosphamide, fludarabine, etoposide) and then CD7 CAR-T cell infusion therapy. After a median follow-up of 15.1 months, the results showed:

 

  1. **Complete Remission (CR):** All patients (n=10) achieved complete remission (CR) after CAR-T cell therapy, though hematologic recovery was incomplete, with grade 4 pancytopenia. As of November 8, 2023 (data cutoff date), 6 patients had not received any further treatment and remained in minimal residual disease (MRD) negative complete remission.

 

  1. **Overall Survival Rate:** The estimated 1-year overall survival rate was 68% [95% Confidence Interval (CI), 43–100].

 

  1. **Disease-Free Survival Rate:** The estimated 1-year disease-free survival rate was 54% (95% CI, 29–100).

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

 

#ASCO2024 #CARTherapy #BloodCancer #CD7CART #CancerResearch #Hematology #MedicalInnovation #CART


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
4 months ago CAR-T

Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan

**Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan**

Professor Li Chunrui’s team at Tongji Hospital in Wuhan successfully conducted a case of chimeric antigen receptor T-cell (CAR-T) immunotherapy for a patient with relapsed and refractory multiple myeloma, offering new life to Swiss patient Thomas.

Thomas, a 54-year-old patient from Switzerland, has been battling multiple myeloma for nearly ten years. Initially diagnosed in 2016, he has endured severe bone pain and undergone multiple rounds of systemic chemotherapy and monoclonal antibody therapy. Although his condition was temporarily controlled, repeated relapses, with the most recent in 2022, made treatment increasingly challenging.

However, the global development of CAR-T therapy has reignited hope. The introduction of FUCASO (Eque-cel), the first fully human CAR-T product in mainland China, has brought new light to Thomas. This groundbreaking treatment not only boasts low immunogenicity but also offers prolonged efficacy, enabling patients to return to a high quality of life.

Thomas ultimately chose to receive the cutting-edge CAR-T therapy at Tongji Hospital, seeking a fundamental breakthrough in his treatment. The apheresis procedure was conducted by the hospital’s top hematology team, who possess international-level expertise and place special emphasis on patient-specific needs and treatment safety. The attending physician elaborated on the apheresis process in an interview, saying, “We precisely collected T-cells from Thomas’s body, then modified these cells in a controlled environment to specifically target multiple myeloma cancer cells. The use of FUCASO greatly enhanced the treatment’s specificity and success rate.”

Thomas expressed high recognition and appreciation for the hospital team’s professionalism and the transparency of the treatment process. Tongji Hospital leveraged its advanced technology and equipment to provide Thomas with a smooth and efficient apheresis experience, ensuring high-quality T-cell collection and paving the way for the subsequent treatment.

Thomas is now filled with confidence and anticipation, looking forward to the new life that CAR-T therapy promises. This new beginning marks a significant step in his treatment journey, injecting new hope into his path to recovery.

We will continue to follow up on the patient’s subsequent treatment and report on the progress.

 

CART MultipleMyeloma FUCASOJourney Equecel TongjiHospital CancerSurvivor BloodCancer Immunotherapy FullyHumanCART CancerTreatment

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.